Skip to content Skip to footer
Subscribe Now
NEWS

Eli Lilly to Acquire Verve Therapeutics for ~$1.3B

Shots: Eli Lilly has entered into a definitive agreement to acquire Verve Therapeutics to advance cardiovascular therapies As per the deal, Lilly will acquire Verve for $10.50/share in an all-cash transaction totaling ~$1B, along with one non-tradeable CVR of $3/share tied to first pts dosing with VERVE-102 for ASCVD in P-III trial by year 10 post-closing;…
June 17, 2025

Read more

Eli Lilly and Camurus
NEWS

Eli Lilly Licenses Camurus’ FluidCrystal Technology to Advance Long-Acting Incretin Products

Shots: Camurus has granted Eli Lilly exclusive global rights to research, develop, manufacture, & commercialize long-acting incretin drugs using Camurus’ FluidCrystal tech for cardiometabolic diseases  As per the deal, Camurus will receive ~$290M in upfront, development & regulatory milestones as well as $580M in sales-based milestones & global net sales-based tiered royalties in mid-single digits…
June 5, 2025

Read more

SiteOne Therapeutics
NEWS

Eli Lilly to Acquire SiteOne Therapeutics for ~$1B, Strengthening its Pain Pipeline

Shots: Eli Lilly has entered into a definitive agreement to acquire SiteOne Therapeutics incl. its asset, STC-004, expanding its pain pipeline  As per the deal, SiteOne shareholders will receive an upfront payment as well as regulatory & commercial milestones for a total consideration of ~$1B in cash     STC-004 is a non-opioid Nav1.8 inhibitor, which will advance into…
May 28, 2025

Read more

Top 20 Biopharma Deal Termination 2024
TOP 20

Top 20 Biopharma Deal Terminations of 2024

Shots:  In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response  In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…
May 14, 2025

Read more

Eli Lilly and Alchemab Therapeutics
NEWS

Eli Lilly Enters a ~$415M Licensing Agreement with Alchemab Therapeutics for ATLX-1282 to Treat Amyotrophic Lateral Sclerosis (ALS)

Shots: Eli Lilly has entered into a licensing agreement with Alchemab for ATLX-1282 to treat ALS & other neurodegenerative conditions As per the deal, Alchemab will receive ~$415M, incl. an upfront payment, potential discovery, development, & commercial payments, as well as royalties, plus will handle early P-I trial activities, with Lilly leading further development &…
May 6, 2025

Read more

Eli Lilly Partners & Creyon Bio
NEWS

Eli Lilly Partners with Creyon Bio for Accelerated Discovery and Development of RNA-Targeted Oligonucleotides for Various Diseases

Shots: Eli Lilly has entered into a global licensing & multi-target research collaboration with Creyon Bio to identify, develop & market novel RNA-targeted oligonucleotide therapies for Lilly’s named targets using Creyon’s AI-powered Oligo Engineering Engine As per the deal, Lilly will get exclusive rights of lead candidates & handle further research, development & marketing upon…
April 30, 2025

Read more

Top 20 Biopharma 2025
TOP 20

Top 20 Biopharma Companies of 2025 

Shots:  Driven by innovation and a steadfast commitment to advancing cutting-edge therapies, the biopharma industry experienced robust growth in 2024, marked by significant revenue milestones  With a projected compound annual growth rate (CAGR) of 12.87%, the global biopharma market is expected to reach $1.41 trillion by 2032. In 2024, Pfizer led the industry with total…
April 24, 2025

Read more

BigHat Biosciences & Eli Lilly
NEWS

BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics

Shots: BigHat Biosciences and Eli Lilly entered into a strategic collaboration to design and develop next-generation therapeutic antibodies using BigHat’s ML-powered Milliner platform and synthetic biology wet lab The collaboration includes up to two antibody programs and support for BigHat’s internal pipeline, including a next-gen ADC for GI cancers entering the clinic in 2026, with…
April 18, 2025

Read more

Load more